Oxitriptan

DB02959

small molecule approved investigational nutraceutical

Deskripsi

5-Hydroxytryptophan (5-HTP), also known as oxitriptan (INN), is a naturally occurring amino acid and metabolic intermediate in the synthesis of serotonin and melatonin. 5-HTP is sold over-the-counter in the United Kingdom, United States and Canada as a dietary supplement for use as an antidepressant, appetite suppressant, and sleep aid, and is also marketed in many European countries for the indication of major depression under trade names like Cincofarm, Levothym, Levotonine, Oxyfan, Telesol, Tript-OH, and Triptum. Several double-blind placebo-controlled clinical trials have demonstrated the effectiveness of 5-HTP in the treatment of depression, though a lack of high quality studies has been noted. More study is needed to determine efficacy in treating depression.

Struktur Molekul 2D

Berat 220.2246
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

5-Hydroxytryptophan is decarboxylated to serotonin (5-hydroxytryptamine or 5-HT) by the enzyme aromatic-L-amino-acid decarboxylase via a vitamin B6 dependent reaction in nervous tissue and in the liver.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

676 Data
Buprenorphine Oxitriptan may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Oxitriptan.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Oxitriptan.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Oxitriptan.
Hydrocodone Oxitriptan may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Oxitriptan.
Magnesium sulfate The therapeutic efficacy of Oxitriptan can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Oxitriptan may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Metyrosine Oxitriptan may increase the sedative activities of Metyrosine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Oxitriptan.
Mirtazapine Oxitriptan may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Oxitriptan.
Orphenadrine Oxitriptan may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Oxitriptan may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Oxitriptan.
Pramipexole Oxitriptan may increase the sedative activities of Pramipexole.
Ropinirole Oxitriptan may increase the sedative activities of Ropinirole.
Rotigotine Oxitriptan may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Oxitriptan.
Sodium oxybate Oxitriptan may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Suvorexant Oxitriptan may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Oxitriptan.
Thalidomide Oxitriptan may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Oxitriptan may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Oxitriptan.
Dicoumarol The risk or severity of adverse effects can be increased when Oxitriptan is combined with Dicoumarol.
Phenindione The risk or severity of adverse effects can be increased when Oxitriptan is combined with Phenindione.
Warfarin The risk or severity of adverse effects can be increased when Oxitriptan is combined with Warfarin.
Phenprocoumon The risk or severity of adverse effects can be increased when Oxitriptan is combined with Phenprocoumon.
Acenocoumarol The risk or severity of adverse effects can be increased when Oxitriptan is combined with Acenocoumarol.
4-hydroxycoumarin The risk or severity of adverse effects can be increased when Oxitriptan is combined with 4-hydroxycoumarin.
Coumarin The risk or severity of adverse effects can be increased when Oxitriptan is combined with Coumarin.
(R)-warfarin The risk or severity of adverse effects can be increased when Oxitriptan is combined with (R)-warfarin.
Ethyl biscoumacetate The risk or severity of adverse effects can be increased when Oxitriptan is combined with Ethyl biscoumacetate.
Fluindione The risk or severity of adverse effects can be increased when Oxitriptan is combined with Fluindione.
Clorindione The risk or severity of adverse effects can be increased when Oxitriptan is combined with Clorindione.
Diphenadione The risk or severity of adverse effects can be increased when Oxitriptan is combined with Diphenadione.
Tioclomarol The risk or severity of adverse effects can be increased when Oxitriptan is combined with Tioclomarol.
(S)-Warfarin The risk or severity of adverse effects can be increased when Oxitriptan is combined with (S)-Warfarin.
Ethanol Oxitriptan may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Azelastine Oxitriptan may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Oxitriptan.
Zimelidine The risk or severity of adverse effects can be increased when Oxitriptan is combined with Zimelidine.
Dapoxetine The risk or severity of adverse effects can be increased when Oxitriptan is combined with Dapoxetine.
Seproxetine The risk or severity of adverse effects can be increased when Oxitriptan is combined with Seproxetine.
Fluvoxamine The risk or severity of adverse effects can be increased when Oxitriptan is combined with Fluvoxamine.
Citalopram The risk or severity of adverse effects can be increased when Oxitriptan is combined with Citalopram.
Duloxetine The risk or severity of adverse effects can be increased when Oxitriptan is combined with Duloxetine.
Trazodone The risk or severity of adverse effects can be increased when Oxitriptan is combined with Trazodone.
Paroxetine The risk or severity of adverse effects can be increased when Oxitriptan is combined with Paroxetine.
Sertraline The risk or severity of adverse effects can be increased when Oxitriptan is combined with Sertraline.
Sibutramine The risk or severity of adverse effects can be increased when Oxitriptan is combined with Sibutramine.
Nefazodone The risk or severity of adverse effects can be increased when Oxitriptan is combined with Nefazodone.
Escitalopram The risk or severity of adverse effects can be increased when Oxitriptan is combined with Escitalopram.
Milnacipran The risk or severity of adverse effects can be increased when Oxitriptan is combined with Milnacipran.
Desvenlafaxine The risk or severity of adverse effects can be increased when Oxitriptan is combined with Desvenlafaxine.
Levomilnacipran The risk or severity of adverse effects can be increased when Oxitriptan is combined with Levomilnacipran.
Indalpine The risk or severity of adverse effects can be increased when Oxitriptan is combined with Indalpine.
Ritanserin The risk or severity of adverse effects can be increased when Oxitriptan is combined with Ritanserin.
Alaproclate The risk or severity of adverse effects can be increased when Oxitriptan is combined with Alaproclate.
Cyproheptadine The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Oxitriptan.
Propiomazine The risk or severity of CNS depression can be increased when Propiomazine is combined with Oxitriptan.
Zopiclone The risk or severity of adverse effects can be increased when Oxitriptan is combined with Zopiclone.
Botulinum toxin type B The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Oxitriptan.
Botulinum toxin type A The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Oxitriptan.
Baclofen Baclofen may increase the central nervous system depressant (CNS depressant) activities of Oxitriptan.
Ethchlorvynol The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Oxitriptan.
Succinylcholine The risk or severity of CNS depression can be increased when Succinylcholine is combined with Oxitriptan.
Eletriptan The risk or severity of CNS depression can be increased when Eletriptan is combined with Oxitriptan.
Enflurane The risk or severity of CNS depression can be increased when Enflurane is combined with Oxitriptan.
Butabarbital The risk or severity of CNS depression can be increased when Butabarbital is combined with Oxitriptan.
Butalbital The risk or severity of CNS depression can be increased when Butalbital is combined with Oxitriptan.
Methysergide The risk or severity of CNS depression can be increased when Methysergide is combined with Oxitriptan.
Cabergoline The risk or severity of CNS depression can be increased when Cabergoline is combined with Oxitriptan.
Phenytoin The risk or severity of CNS depression can be increased when Phenytoin is combined with Oxitriptan.
Topiramate The risk or severity of CNS depression can be increased when Topiramate is combined with Oxitriptan.
Clemastine The risk or severity of CNS depression can be increased when Clemastine is combined with Oxitriptan.
Etomidate The risk or severity of CNS depression can be increased when Etomidate is combined with Oxitriptan.
Morphine The risk or severity of CNS depression can be increased when Morphine is combined with Oxitriptan.
Talbutal The risk or severity of CNS depression can be increased when Talbutal is combined with Oxitriptan.
Pentobarbital The risk or severity of CNS depression can be increased when Pentobarbital is combined with Oxitriptan.
Zolmitriptan The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Oxitriptan.
Codeine The risk or severity of CNS depression can be increased when Codeine is combined with Oxitriptan.
Dihydroergotamine The risk or severity of CNS depression can be increased when Dihydroergotamine is combined with Oxitriptan.
Tolcapone The risk or severity of CNS depression can be increased when Tolcapone is combined with Oxitriptan.
Hydromorphone The risk or severity of CNS depression can be increased when Hydromorphone is combined with Oxitriptan.
Cetirizine The risk or severity of CNS depression can be increased when Cetirizine is combined with Oxitriptan.
Trimethadione The risk or severity of CNS depression can be increased when Trimethadione is combined with Oxitriptan.
Chlorzoxazone The risk or severity of CNS depression can be increased when Chlorzoxazone is combined with Oxitriptan.
Thiethylperazine The risk or severity of CNS depression can be increased when Thiethylperazine is combined with Oxitriptan.
Palonosetron The risk or severity of CNS depression can be increased when Palonosetron is combined with Oxitriptan.
Dexbrompheniramine The risk or severity of CNS depression can be increased when Dexbrompheniramine is combined with Oxitriptan.
Metocurine iodide The risk or severity of CNS depression can be increased when Metocurine iodide is combined with Oxitriptan.
Secobarbital The risk or severity of CNS depression can be increased when Secobarbital is combined with Oxitriptan.
Methocarbamol The risk or severity of CNS depression can be increased when Methocarbamol is combined with Oxitriptan.
Triprolidine The risk or severity of CNS depression can be increased when Triprolidine is combined with Oxitriptan.
Meperidine The risk or severity of CNS depression can be increased when Meperidine is combined with Oxitriptan.
Metharbital The risk or severity of CNS depression can be increased when Metharbital is combined with Oxitriptan.
Quinine The risk or severity of CNS depression can be increased when Quinine is combined with Oxitriptan.
Methohexital The risk or severity of CNS depression can be increased when Methohexital is combined with Oxitriptan.

Target Protein

Tryptophan--tRNA ligase 2 trpS2

Referensi & Sumber

Synthesis reference: British Patent 845,034.
Artikel (PubMed)
  • PMID: 15893130
    Turner EH, Blackwell AD: 5-Hydroxytryptophan plus SSRIs for interferon-induced depression: synergistic mechanisms for normalizing synaptic serotonin. Med Hypotheses. 2005;65(1):138-44.
  • PMID: 11869656
    Shaw K, Turner J, Del Mar C: Tryptophan and 5-hydroxytryptophan for depression. Cochrane Database Syst Rev. 2002;(1):CD003198.
  • PMID: 6983619
    Rahman MK, Nagatsu T, Sakurai T, Hori S, Abe M, Matsuda M: Effect of pyridoxal phosphate deficiency on aromatic L-amino acid decarboxylase activity with L-DOPA and L-5-hydroxytryptophan as substrates in rats. Jpn J Pharmacol. 1982 Oct;32(5):803-11.
  • PMID: 18445233
    Nakatani Y, Sato-Suzuki I, Tsujino N, Nakasato A, Seki Y, Fumoto M, Arita H: Augmented brain 5-HT crosses the blood-brain barrier through the 5-HT transporter in rat. Eur J Neurosci. 2008 May;27(9):2466-72. doi: 10.1111/j.1460-9568.2008.06201.x.
  • PMID: 39668
    Bouchard S, Roberge AG: Biochemical properties and kinetic parameters of dihydroxyphenylalanine--5-hydroxytryptophan decarboxylase in brain, liver, and adrenals of cat. Can J Biochem. 1979 Jul;57(7):1014-8.
  • PMID: 1088369
    Amamoto T, Sarai K: On the tryptophan-serotonin metabolism in manic-depressive disorders. Changes in plasma 5-HT and 5-HIAA levels and urinary 5-HIAA excretion following oral loading of L-5HTP in patients with depression. Hiroshima J Med Sci. 1976 Sep;25(2-3):135-40.
  • PMID: 6175178
    Magnussen I, Jensen TS, Rand JH, Van Woert MH: Plasma accumulation of metabolism of orally administered single dose L-5-hydroxytryptophan in man. Acta Pharmacol Toxicol (Copenh). 1981 Sep;49(3):184-9.
  • PMID: 9727088
    Birdsall TC: 5-Hydroxytryptophan: a clinically-effective serotonin precursor. Altern Med Rev. 1998 Aug;3(4):271-80.
Menampilkan 8 dari 12 artikel.

Contoh Produk & Brand

Produk: 1 • International brands: 4
Produk
  • Hypnosom
    Tablet • - • Oral • US
International Brands
  • Cincofarm
  • Levothym — Lundbeck
  • Quietim — Nativelle
  • Tript-OH

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul